Keyword: Aurobindo Pharma
Amgen pays $2.7 billion for a 20.5% stake in BeiGene. AstraZeneca tightens its ties to China as China approves a controversial Alzheimer's drug.
In eyeing Novartis' deal to sell assets to Aurobindo, the Federal Trade Commission is reportedly delving into a lawsuit the generics maker faces.
India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.
FTC review delays Sandoz-Aurobindo generics deal. Manufacturing questions push back Zolgensma decision in Japan. AZ expects mid-teens China growth.
What's taking Novartis' Sandoz and Aurobindo so long in their $1 billion U.S. generics oral solids and dermatology deal? FTC happened.
Aurobindo and Glenmark are cited by the FDA. Takeda inks IBD discovery pact with Prometheus. Ascletis recruits Novartis veteran as CSO.
India’s Aurobindo, which has been racking up FDA actions right and left, acknowledged Monday a recent agency inspection resulted in a Form 483.
Avanir pays $116 million in Neudexta kickback suits; China unveils results for a procurement scheme; Aurobindo founder faces insider trading fine.
Pfizer and Aurobindo’s 2009 deal was a boon for the Indian drugmaker in taking its products global. Turns out one exec wanted more from the agreement.
BeiGene rebuffs claims that it inflated drug sales records; Sumitomo Dainippon pays $3 billion upfront for five "vants"; Genentech settles with JHL Biotech.